Prostate cancer is one of the most common types of cancer caused among a large populace across the world. The growing cases of prostate cancer are a clarion call for extensive treatment options. Hence, based on this aspect, the hormone refractory prostate cancer market will record phenomenal growth between 2019 and 2029.
According to the American Cancer Society, about 1 person in 9 will be a prostate cancer patient during his lifetime. About 6 cases in 10 are detected in men who are above the age of 65 or older. This highlights that prostate cancer is more prevalent across the geriatric population. With the expanding geriatric population, the hormone refractory prostate cancer market is expected to add extra stars of growth.
Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6793
About 191,930 new cases of prostate cancer and 33,330 deaths due to prostate cancer were recorded recently in the U.S. according to the American Cancer Society. More than 3.1 million in the U.S. have been diagnosed with prostate cancer at some point in their life. Therefore these statistics highlight the rising cases, thus increasing the growth opportunities for the hormone refractory prostate cancer market.
Robust Prostate Cancer Testing Mechanisms Inviting Good Growth Prospects
The hormone refractory prostate cancer market may garner extensive growth mainly due to prostate-specific antigen testing. This leads to the maximum detection of these cases and hence, brings tremendous growth opportunities.
Expensive Drugs to Prove as Key Growth Dampener
The high costs associated with the drugs related to hormone refractory prostate cancer may serve as an obstacle in the growth. However, the players, through research and development activities are trying to develop drugs that are both affordable and effective for the global populace. This may stop the growth leak.
North America may emerge as a champion of growth across the assessment period due to the latest developments regarding treatment and the presence of robust health infrastructure.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6793